The cyclin-dependent kinase 2 (cdk2) is a serine/threonine protein kinase that plays a key role in the cell cycle control system of all eukaryotic organisms. It has been a much studied drug target for potential anticancer therapy. Most cdk2 inhibitors in clinical development target almost exclusively the catalytic ATP-binding pocket of cdk2. However, several five amino-acid peptide inhibitors that are directed towards a noncatalytic binding pocket of cdk2 are reported here. Upon binding to this new pocket located at the cdk2 and cyclin interface, these peptide inhibitors are found to disrupt the cdk2/cyclin E complex partially and diminish its kinase activity in vitro.
A novel binding pocket of cyclin-dependent kinase 2
Creators
Hao Chen - George Washington University
Rachel Van Duyne - George Washington University
Naigong Zhang - George Washington University
Fatah Kashanchi - George Washington University
Chen Zeng - George Washington University
Publication Details
Proteins, structure, function, and bioinformatics, v 74(1), pp 122-132
Publisher
Wiley
Number of pages
11
Grant note
George Washington University REF, SE
AI065236; AI043894 / NIH; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA
R21AI065236 / NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)
DMR0313129 / NSF; National Science Foundation (NSF)
Conrad; United States Agency for International Development (USAID)
Resource Type
Journal article
Language
English
Academic Unit
Pharmacology and Physiology
Web of Science ID
WOS:000261757900011
Scopus ID
2-s2.0-58949085676
Other Identifier
991021903124304721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool: